anti-CD28/anti-TAA-2 bispecific antibody (Rondo Therapeutics)

N/A

Report date: 2026/03/19 16:52:56

Base Information

Drug Nameanti-CD28/anti-TAA-2 bispecific antibody (Rondo Therapeutics)
Drug Alias NameRondo-Program 2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 agonistsT lymphocytes stimulantsImmunostimulants
TargetsT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsOvarian Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRondo Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesRondo Therapeutics
Inactive CompaniesN/A
Active IndicationsOvarian Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A